PP-036 Blinatumomab: organisational and economic optimisation of treatment and proposal for scheduled patient care. (25th February 2017)
- Record Type:
- Journal Article
- Title:
- PP-036 Blinatumomab: organisational and economic optimisation of treatment and proposal for scheduled patient care. (25th February 2017)
- Main Title:
- PP-036 Blinatumomab: organisational and economic optimisation of treatment and proposal for scheduled patient care
- Authors:
- Hassani, L
Osman, N
Nguyen, S
Kouari, FEL
Bekari, L
Tilleul, P
Abellanger, - Abstract:
- Abstract : Background: Blinatumomab (Blincyto) is an antibody bispecific indicated in relapsed or refractory B LAL. A single cycle of treatment of blinatumomab consists of 4 weeks of continuous intravenous infusion at a dose of 9 µg/day for the first week and then 28 µg/day followed by a 2 week treatment free interval. The maximums storage time of the infusion is 4 days. Continuous infusion can be given at home with an ambulatory pump. The cost of a 35 µg vial is €2880. Purpose: The objective of this study was to propose optimal organisation to limit the cost of the treatment Material and methods: A simple mathematical calculation was used to evaluate the cost of various possibilities for the administration schedule. Several points were studied: (1) decrease number of bags prepared; (2) optimise the number of vials used; (3) determinate the best administration schedule to reduce changing infusion bag; and (4) avoid changing infusion bag on weekend to reduce costs. Results: (1) Preparation takes account of stability and dose: the first week 2 bags are needed and the following 3 weeks following 6 bags are needed so the minimum number of bags is eight. (2) 651 µg is the efficacy dose for the first cycle, corresponding to 17 vials but the short storage duration of reconstituted vial (24 hours) constrains the use of an additional vial: 18 vials (€51 840). (3) The best schedule for reducing changing the infusion bag must include the 28 µg dose realised in J8 duringAbstract : Background: Blinatumomab (Blincyto) is an antibody bispecific indicated in relapsed or refractory B LAL. A single cycle of treatment of blinatumomab consists of 4 weeks of continuous intravenous infusion at a dose of 9 µg/day for the first week and then 28 µg/day followed by a 2 week treatment free interval. The maximums storage time of the infusion is 4 days. Continuous infusion can be given at home with an ambulatory pump. The cost of a 35 µg vial is €2880. Purpose: The objective of this study was to propose optimal organisation to limit the cost of the treatment Material and methods: A simple mathematical calculation was used to evaluate the cost of various possibilities for the administration schedule. Several points were studied: (1) decrease number of bags prepared; (2) optimise the number of vials used; (3) determinate the best administration schedule to reduce changing infusion bag; and (4) avoid changing infusion bag on weekend to reduce costs. Results: (1) Preparation takes account of stability and dose: the first week 2 bags are needed and the following 3 weeks following 6 bags are needed so the minimum number of bags is eight. (2) 651 µg is the efficacy dose for the first cycle, corresponding to 17 vials but the short storage duration of reconstituted vial (24 hours) constrains the use of an additional vial: 18 vials (€51 840). (3) The best schedule for reducing changing the infusion bag must include the 28 µg dose realised in J8 during hospitalisation. (4) Changing infusion bag can be avoided during the weekend if the day of treatment initiation is a Saturday; it will be twice at the weekend if the initiation day is Monday or Thursday. Conclusion: The efficient scheduled for patient care corresponds to 8 preparations with 18 vials. The correct administration schedule is the following: J1, J5, J8, J9, J13, J17, J21, J25. Initiation of treatment should start preferably on a Saturday and avoid as much as possible Monday and Thursday. This practice can be applied in all hospitals and generates the best treatment price. No conflict of interest … (more)
- Is Part Of:
- European journal of hospital pharmacy. Volume 24(2017)Supplement 1
- Journal:
- European journal of hospital pharmacy
- Issue:
- Volume 24(2017)Supplement 1
- Issue Display:
- Volume 24, Issue 1 (2017)
- Year:
- 2017
- Volume:
- 24
- Issue:
- 1
- Issue Sort Value:
- 2017-0024-0001-0000
- Page Start:
- A217
- Page End:
- A217
- Publication Date:
- 2017-02-25
- Subjects:
- Pharmacy -- Periodicals
Hospital pharmacies -- Periodicals
615.1 - Journal URLs:
- http://www.bmj.com/archive ↗
http://ejhp.bmj.com/ ↗ - DOI:
- 10.1136/ejhpharm-2017-000640.483 ↗
- Languages:
- English
- ISSNs:
- 2047-9956
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 18725.xml